Veradermics Inc. (MANE)
NYSE NYSE Primary 
Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis
Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE's late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01's regulatory approval and commercialization as a first-in-class oral therapy.
Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss Transcript
Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss Transcript
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill
Jefferies is initiating coverage of Veradermics with a 'buy' rating, betting that a smarter formulation of an old drug could unlock a $2 billion market Minoxidil has been around for decades. Millions of people rub it into their scalps every day, and a growing number take low-dose oral versions off-label.
